Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- COVID- 19 Updated

Report ID: AMI-38265599 | Publihed: 01-Jul-2020 | No of Pages: 216


USD 3995
USD 5795


Publish Date:


Total pages:


REPORT HIGHLIGHT Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016-2027
The pulmonary arterial hypertension (PAH) market is estimated to represent a global market of USD 6.41 billion by 2019 with growth rate of 5.6%.
Market Dynamics
According to the World Health Organization (WHO), pulmonary arterial hypertension is a debilitating condition, characterized by the elevated pulmonary vascular resistance and pulmonary arterial pressure. The condition may lead to the failure of right ventricular or patient’s death. PAH can be hereditable, idiopathic, or associated with conditions such as congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAH is categorized under rate disease as the prevalence of this disorder is very low, with an estimated prevalence around 15 to 50 cases per million population. However, the prevalence of this disorder is increasing during the past few years owing to the risk factors such as smoking, tobacco consumption, sedentary lifestyle, and other idiopathic conditions.
The market for Pulmonary Arterial Hypertension is primarily driven by the favourable government initiatives for the development of orphan drugs. The government provides benefits in terms of enhanced patent protection term, tax incentives etc. Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are the two important acts which facilitate the distribution and ethical usage of orphan therapeutics. For instance, The ODA facilitates tax credits up to 50.0% of overall research cost, protocol assistance, waiver in U.S. FDA fees and clinical tax incentives. This fact would, in turn, encourage key players to invest in this industry, augmenting the market growth to great extent.
The sudden challenges created by the ongoing COVID-19 outbreak is captured effectively to exhibit the long term growth projections in the Pulmonary Arterial Hypertension (PAH) Market report. The top growth segments and marginal growth sectors of the Pulmonary Arterial Hypertension (PAH) Market are identified with precision for a better growth perspective.
Drug Class Takeaway
In terms of drug class, the industry is categorized as Prostacyclin and Analogs, Soluble Guanylyl Cyclase (SGC) Stimulators, Endothelin receptor antagonist (ERA) and Phosphodiesterase-5. An ERA dominated the market with a substantial share of over 40% throughout the study period. On another hand, drugs targeting the prostacyclin pathway reported global sales of over USD 2.3 billion in 2017. Iloprost (Ventavis from Actelion), Epoprostenol (Veletri from Actelion and Flolan from GSK), Treprostinil (Tyvaso, Remodulin, and Orenitram from United Therapeutics) are some of the prostacyclin analogs approved by the U.S. FDA for the treatment of PAH. SGC stimulators are the lowest revenue generating drug class owing to the availability of other effective therapeutics.
Regional Takeaway
Geographically, the industry is categorized into North America, Europe, Asia Pacific and Rest of the World. Developed regions such as North America and Europe accounted for the highest share of the global market.
Key Vendor Takeaway
Companies such as Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer, and Merck are some of the prominent participants in the global Pulmonary Arterial Hypertension market. Apart of it, the presence of small players is noticeable too. For instance, Actelion Pharmaceuticals is developing a Macitentan drug for pediatric PAH. The company has initiated phase III (titled as “Tomorrow”) study which will evaluate the effect of macitentan on children with PAH. Also, in October 2015, Gilead Sciences, Inc.’s new combination treatment of Tadalafil and Letairis is approved by the U.S. FDA. Such facts will further help key players to enhance their market presence.
The years considered for the study are:

Historical Year – 2016 to 2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2027

The proposed reports analyse and evaluates the COVID-19 impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.

The scope of this report covers the market by its major segments, which include as follows:
Prostacyclin and Analogs
Soluble Guanylyl Cyclase (SGC) Stimulators
Endothelin receptor antagonist (ERA)
North America
Rest of Europe
Asia Pacific
Rest of APAC
Rest of the World
Middle East and Africa
Latin America

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.